Entrada Therapeutics (TRDA) Accumulated Depreciation & Amortization: 2022-2025
Historic Accumulated Depreciation & Amortization for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $10.2 million.
- Entrada Therapeutics' Accumulated Depreciation & Amortization rose 20.15% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.2 million, marking a year-over-year increase of 43.58%. This contributed to the annual value of $9.4 million for FY2024, which is 59.11% up from last year.
- Per Entrada Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $10.2 million for Q3 2025, which was down 10.28% from $11.3 million recorded in Q2 2025.
- Entrada Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $11.3 million for Q2 2025, and its period low was $1.8 million during Q1 2022.
- In the last 3 years, Entrada Therapeutics' Accumulated Depreciation & Amortization had a median value of $7.6 million in 2024 and averaged $7.6 million.
- Data for Entrada Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY soared of 112.62% (in 2023) over the last 5 years.
- Quarterly analysis of 4 years shows Entrada Therapeutics' Accumulated Depreciation & Amortization stood at $3.3 million in 2022, then spiked by 79.43% to $5.9 million in 2023, then skyrocketed by 59.11% to $9.4 million in 2024, then grew by 20.15% to $10.2 million in 2025.
- Its Accumulated Depreciation & Amortization was $10.2 million in Q3 2025, compared to $11.3 million in Q2 2025 and $10.3 million in Q1 2025.